Literature DB >> 19161911

Matrix metalloproteinases and their multiple roles in neurodegenerative diseases.

Gary A Rosenberg1.   

Abstract

Matrix metalloproteinases (MMPs) and proteins containing a disintegrin and metalloproteinase domain (ADAM) are important in neuroinflammation, and recent studies have linked their actions to neurodegenerative disorders. MMPs act as cell-surface sheddases and can affect cell signalling initiated by growth factors or death receptors. Four tissue inhibitors of metalloproteinases (TIMPs) regulate metalloproteinase activity. These proteases increase the permeability of the blood-brain barrier, which can cause oedema, haemorrhage, and cell death. MMPs also participate in tissue repair by promoting angiogenesis and neurogenesis. In vascular cognitive impairment, MMPs change permeability of the blood-brain barrier and might contribute to white matter damage. MMPs and ADAMs might contribute to the formation and degradation of amyloid proteins in Alzheimer's disease and cause death of dopaminergic neurons in Parkinson's disease. In this Review, by examining the effects of neuroinflammation, we try to understand the role that MMPs might have in neurodegenerative diseases. Therapeutic strategies that use inhibitors of MMPs could represent potential novel treatments for neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161911     DOI: 10.1016/S1474-4422(09)70016-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  206 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

2.  Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.

Authors:  Anika M S Hartz; Björn Bauer; Emma L B Soldner; Andrea Wolf; Sandra Boy; Roland Backhaus; Ivan Mihaljevic; Ulrich Bogdahn; Hans H Klünemann; Gerhard Schuierer; Felix Schlachetzki
Journal:  Stroke       Date:  2011-11-23       Impact factor: 7.914

Review 3.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

4.  Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.

Authors:  Markus Morawski; Gert Brückner; Carsten Jäger; Gudrun Seeger; Russel T Matthews; Thomas Arendt
Journal:  Brain Pathol       Date:  2012-01-13       Impact factor: 6.508

5.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

Review 6.  Blood-brain barrier breakdown in acute and chronic cerebrovascular disease.

Authors:  Yi Yang; Gary A Rosenberg
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

7.  Degrading epilepsy: the role of extracellular proteases and the extracellular matrix.

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

8.  Strain differences in the effects of chronic corticosterone exposure in the hippocampus.

Authors:  G E Hodes; B R Brookshire; T E Hill-Smith; S L Teegarden; O Berton; I Lucki
Journal:  Neuroscience       Date:  2012-06-23       Impact factor: 3.590

Review 9.  Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection.

Authors:  Kenneth H Clark; Clayton A Wiley; Charles W Bradberry
Journal:  Neurotox Res       Date:  2012-06-20       Impact factor: 3.911

10.  Excitatory and Mitogenic Signaling in Cell Death, Blood-brain Barrier Breakdown, and BBB Repair after Intracerebral Hemorrhage.

Authors:  Da-Zhi Liu; Frank R Sharp
Journal:  Transl Stroke Res       Date:  2012-03-15       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.